Evidence map›Paper›PMID 40525305›Full record

ArticleACS applied materials & interfaces2025

A Permeabilization Workflow To Enable Specific Multiplexed Profiling Using SERS Nanoparticles.

Pegah Bagheri, Olga E Eremina, Nicholas Dorgan, Joshua Millstein, Cristina Zavaleta

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pegah BagheriAlfred E. Mann Department of Biomedical Engineering, University of Southern California, 36- McClintock Ave, Los Angeles, California 90089, United States.ORCID 0000-0001-6853-6037
Olga E EreminaAlfred E. Mann Department of Biomedical Engineering, University of Southern California, 36- McClintock Ave, Los Angeles, California 90089, United States.ORCID 0000-0002-2776-4743
Nicholas DorganAlfred E. Mann Department of Biomedical Engineering, University of Southern California, 36- McClintock Ave, Los Angeles, California 90089, United States.
Joshua MillsteinKeck School of Medicine of USC, Department of Population and Public Health Sciences, 1845 N Soto St, Los Angeles, California 90032, United States.
Cristina ZavaletaAlfred E. Mann Department of Biomedical Engineering, University of Southern California, 36- McClintock Ave, Los Angeles, California 90089, United States.

Funding

Development of a New Multiplexed Imaging Strategy for Immunoprofiling using Raman-Active NanoparticlesR01CA293950 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PARAG Kumar MALLICK, Cristina L. Zavaleta · 2024 to 2026
$3.1M
Supplement to Support the Development of a New Multiplexed Imaging Tool using Raman Spectroscopy for Breast CancerR01EB033918 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZAVALETA, CRISTINA L. · 2023 to 2024
$1.4M
NCI NIH HHS R01 CA293950NIBIB NIH HHS R01 EB033918
6 · The paper itself

Abstract

Surface-enhanced Raman scattering nanoparticles (SERS NPs) are powerful tools for cellular-specific targeting and multiplexed biomarker detection. While they have been effective in labeling extracellular receptors, their application to intracellular targets has been limited by poor membrane permeability and endosomal trapping. Here, we present an optimized permeabilization and staining strategy that enables robust intracellular targeting with SERS NPs. Using breast cancer as a model system, we focused on three clinically relevant biomarkers─human epidermal growth factor 2 (HER2), which has both extracellular and intracellular targets, and estrogen receptor (ER) and progesterone receptor (PR), which are exclusively located inside the cells─to demonstrate the ability of our platform to detect both extracellular and intracellular targets. We conjugated SERS NPs with anti-HER2 antibodies to assess specific binding efficiency across breast cancer cell lines with varying HER2 expression. Flow cytometry revealed a strong correlation between HER2 expression and the specific-to-nonspecific binding ratio, demonstrating over 100-fold specificity for HER2-overexpressing cells. Fluorescence and Raman imaging confirmed high specificity and sensitivity. To extend this approach to intracellular targets, we evaluated three permeabilization agents─Tween 20, Triton X-100, and methanol─and identified Triton X-100 as optimal. It enabled ∼160 nm SERS NPs to access the intracellular space while preserving cell viability. SERS NPs conjugated with anti-ER and anti-PR antibodies revealed significant biomarker binding without compromising cell health, revealing the capability to specifically profile intracellular biomarkers with varying expression levels of ER and PR. Furthermore, multiplexed detection was demonstrated using a cocktail of SERS NPs targeting HER2, ER, and PR in mixed cell populations, mimicking clinical scenarios such as liquid biopsies. Even when target-positive cells were present at low abundance, the NPs retained selective binding and detection capability. Overall, our findings advance the potential of SERS NPs for enhancing breast cancer diagnostics through accurate, multiplexed biomarker targeting.

Indexed as

Breast NeoplasmsMetal NanoparticlesBiomarkers, TumorCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansReceptors, EstrogenReceptors, ProgesteroneSpectrum Analysis, RamanBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesteronebreast cancer cell imagingcell permeabilizationmultiplexed imagingRaman spectroscopySERS nanoparticles

Identifiers

PMID40525305
PMCPMC12337637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.